Skip to main
SKIN
SKIN logo

SKIN Stock Forecast & Price Target

SKIN Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 30%
Buy 10%
Hold 50%
Sell 10%
Strong Sell 0%

Bulls say

Beauty Health Co. has demonstrated strong growth in consumable revenue, which rose 18% to $46.4 million, while international sales experienced a significant increase of 51%, particularly in the APAC region, showcasing a robust expansion strategy. The company's installed base of HydraFacial devices grew by 23% year-over-year, indicating strong demand for its products, and market penetration in China is indicative of further growth potential. Additionally, projected annualized cost savings of over $15 million due to manufacturing optimization could enhance profitability, despite current challenges with product issues and special charges.

Bears say

The Beauty Health Company's recent financial performance has raised significant concerns, as the revenue of $97 million in 3Q23 substantially fell short of both internal estimates and market consensus, triggering a downward revision of 2023 sales guidance from $460-$480 million to $385-$400 million. The company also reported an adjusted EBITDA of $9.1 million, missing expectations by a considerable margin, while lowering its adjusted EBITDA margin outlook for the year to a drastically reduced 5-6% from the previously anticipated 18-19%. Furthermore, the suspension of long-term financial targets for 2025, alongside the departure of key executives and restructuring charges related to product issues, further underscores the challenges Beauty Health faces in attaining sustainable profitability and growth in a competitive market.

SKIN has been analyzed by 10 analysts, with a consensus rating of Buy. 30% of analysts recommend a Strong Buy, 10% recommend Buy, 50% suggest Holding, 10% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of The Beauty Health Company and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About The Beauty Health Company (SKIN) Forecast

Analysts have given SKIN a Buy based on their latest research and market trends.

According to 10 analysts, SKIN has a Buy consensus rating as of Jul 4, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.28, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.28, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

The Beauty Health Company (SKIN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.